Top News
ALK-Rearranged NSCLC Linked to Higher Venous and Arterial Thrombotic Risk
First-Line Pembrolizumab Outperforms Standard-of-Care Chemotherapy in Metastatic MSI-H/dMMR Colorectal Cancer
No OS Benefit After Addition of Early Locoregional Therapy to Optimal Systemic Therapy in the Setting of De Novo Metastatic Breast Cancer
Adjuvant Osimertinib Improved Disease-Free Survival in Locally Advanced NSCLC
KRd Fails to Improve Outcomes Compared With VRd in Newly Diagnosed MM
Avelumab Shown to Prolong Survival in Advanced Urothelial Carcinoma
CheckMate 9LA: Nivolumab/Ipilimumab Plus Chemotherapy Improved Overall Survival in Non-Small Cell Lung Cancer
Promising Early Results for Use of an Oral THC/CBD Extract As Secondary Prophylaxis in the Setting of CINV
Less Than 50% of Patients With Cancer Received NCCN-Concordant Care in California From 2004 to 2016
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
ASCO 2020 Coverage
News coverage from the American Society of Clinical Oncology 2020 virtual meeting. -
Investigating CAR-T Efficacy Limitations in Chronic Lymphocytic Leukemia
Efficacy limitations of CAR-T therapy in CLL may not be due to defects in the CAR-T product, but rather, to characteristics of the tumor cells. -
Vaccinia Virus and Immune Checkpoint Inhibitors: A Viable Combination in Advanced RCC?
Initial data from a phase 1b trial shows encouraging results. -
Outpatient CAR-T Therapy May Offer Cost Savings, but More Data Are Needed
Administering CAR-T cell therapy in the outpatient community setting is estimated to save more than $30,000 per patient. -
Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing. -
No Solid Evidence to Support GEP Testing in Thin Melanoma
Most studies that have looked at 31-GEP testing in melanoma have been retrospective or prospective, and did not involve a comparator group. -
Neoadjuvant Nivolumab Appears Promising in Merkel Cell Carcinoma
A small phase 1/2 study shows high pCR rates.
More Features
Navigating COVID-19: Self-Care Strategies for Oncology Professionals
A review of techniques oncology nurses can use to help themselves cope with their feelings as they navigate through the effects of the COVID-19 pandemic on their practice, their patients, and themselves.
Social Workers Are Underutilized in Oncologic Pain Management
Expertise in the use of nonpharmacologic pain management techniques and therapies allow masters-prepared social workers to be an integral member of a multidisciplinary cancer care team.
Clotting and COVID: New Guidelines in the Works to Treat Coagulopathies in Patients With COVID-19
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Radiation Therapy for Hematologic Cancers During the COVID-19 Pandemic
ILROG has issued guidelines on alternative radiation treatment methods to combat limited treatment resources for cancer patients during the COVID-19 pandemic.
